Related Experiment Video

Updated: May 24, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

[Antiviral treatment of chronic hepatitis C]

Annemarie Berger1

  • 1Institut für Medizinische Virologie, Klinikum der Johann Wolfgang Goethe-Universität, Paul-Ehrlich-Str 40, 60596 Frankfurt am Main. Annemarie.Berger@em.uni-frankfurt.de

Medizinische Monatsschrift Fur Pharmazeuten
|March 10, 2012
PubMed

Insights

Hepatitis C treatment remains challenging, with standard therapy succeeding in 50-80% of cases. New direct-acting antivirals offer improved options, particularly for difficult-to-treat genotypes.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Context:

  • Chronic hepatitis C virus (HCV) infection presents significant therapeutic challenges.
  • Current standard treatment involves pegylated interferon alpha and ribavirin, with variable success rates (50-80%) dependent on HCV genotype and patient response.
  • Limited efficacy and duration requirements necessitate novel treatment strategies.

Purpose:

  • To review the current landscape of hepatitis C therapy.
  • To introduce the advent and potential of direct-acting antivirals (DAAs) in HCV treatment.
  • To highlight the role of new protease inhibitors in managing challenging HCV genotypes.

Summary:

  • The development of direct-acting antivirals (DAAs) marks a significant advancement in managing chronic hepatitis C.
  • Boceprevir and telaprevir, approved HCV protease inhibitors, offer new hope, especially for patients with treatment-resistant HCV genotype 1.
  • These DAAs are currently administered in combination with standard therapy (pegylated interferon and ribavirin) to mitigate antiviral resistance.

Impact:

  • DAAs represent a paradigm shift in hepatitis C management, potentially improving cure rates and shortening treatment durations.
  • The introduction of targeted therapies like boceprevir and telaprevir addresses unmet needs for specific patient populations.
  • Further research and clinical application of DAAs are expected to enhance patient outcomes and reduce the global burden of hepatitis C.

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...